Pear Bio

Pear Bio is a functional precision medicine company that develops personalized cancer treatment tests and novel therapeutics. The platform takes tumor biopsies from patients, converts them into 3D immune-microtumors, and tests multiple treatment options side-by-side to predict response and match patients with effective therapies. Excess tissue is characterized to identify new drug targets for cancers with high unmet need. Founded in 2017, Pear Bio serves both oncology drug discovery teams and individual cancer patients through its personalized testing services and computational biology platform.